Alkermes (ALKS) Non-Current Debt (2011 - 2026)

Alkermes (ALKS) posted quarterly Non-Current Debt of $1.5 billion for Q2 2026, little changed quarter-over-quarter from $1.5 billion in Q1 2026.

Alkermes (ALKS) Non-Current Debt (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Non-Current Debt for 15 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

In Q2 2026, Non-Current Debt changed N/A year-over-year to $1.5 billion; the TTM figure through Jun 2026 stood at $1.5 billion (changed N/A YoY), while the FY2023 annual figure was $287.7 million, down 0.88% from the prior year.
Non-Current Debt held at $1.5 billion in Q2 2026 per ALKS's latest filing, from $1.5 billion in the prior quarter.
Across five years, Non-Current Debt topped out at $1.5 billion in Q1 2026 and bottomed at $285.8 million in Q3 2024.
Historically, Non-Current Debt has averaged $472.3 million across 4 years, with a median of $289.6 million in 2023.
Annual changes were most pronounced in 2022 — Non-Current Debt retreated 0.86% — and 2024, when it retreated 0.88%.
Alkermes' Non-Current Debt stood at $290.3 million in 2022, then slipped by 0.88% to $287.7 million in 2023, then fell by 0.66% to $285.8 million in 2024, then soared by 416.62% to $1.5 billion in 2026.
Business Quant data shows ALKS's Non-Current Debt at $1.5 billion in Q2 2026, $1.5 billion in Q1 2026, and $285.8 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	-8.44 Bn
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	12.09 Bn
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	27.73 Bn
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	11.61 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.85 Bn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	130.00 Mn
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	1.48 Bn

Download Data